<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796899</url>
  </required_header>
  <id_info>
    <org_study_id>EP0007</org_study_id>
    <secondary_id>2012-001358-25</secondary_id>
    <nct_id>NCT01796899</nct_id>
  </id_info>
  <brief_title>Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-center, Open-label, 5-way Crossover, Single-dose Bioavailability/Bioequivalence Comparison of Brivaracetam Oral Tablets (10 mg, 50 mg,75 mg, and 100 mg) and Brivaracetam Intravenous Bolus Injection (100 mg) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the bioavailability/bioequivalence of Brivaracetam oral tablets (10 mg, 50 mg,&#xD;
      75 mg and 100 mg) and Brivaracetam intravenous injection (100 mg) in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration of Brivaracetam dose-normalized to the 50 mg reference treatment (Cmax)</measure>
    <time_frame>Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification dose-normalized to the 50 mg reference treatment (AUC[0-t])</measure>
    <time_frame>Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to infinity dose-normalized to the 50 mg reference treatment (AUC)</measure>
    <time_frame>Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life of Brivaracetam</measure>
    <time_frame>Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration of Brivaracetam (tmax)</measure>
    <time_frame>Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance of Brivaracetam (CL/F)</measure>
    <time_frame>Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of Brivaracetam distribution at the terminal elimination phase</measure>
    <time_frame>Pharmacokinetic samples will be taken predose and 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Brivaracetam 10 mg oral tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.&#xD;
Strength: 10 mg&#xD;
Form: Oral tablet&#xD;
Frequency: Once daily&#xD;
Duration: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 50 mg oral tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.&#xD;
Strength: 50 mg&#xD;
Form: Oral tablet&#xD;
Frequency: Once daily&#xD;
Duration: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 75 mg oral tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.&#xD;
Strength: 75 mg&#xD;
Form: Oral tablet&#xD;
Frequency: Once daily&#xD;
Duration: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 100 mg oral tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.&#xD;
Strength: 100 mg&#xD;
Form: Oral tablet&#xD;
Frequency: Once daily&#xD;
Duration: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.&#xD;
Strength: 100 mg (10 mg/mL)&#xD;
Form: Intravenous bolus injection&#xD;
Frequency: Once daily&#xD;
Duration: 1 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brivaracetam 10 mg oral tablet</intervention_name>
    <arm_group_label>Brivaracetam 10 mg oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brivaracetam 50 mg oral tablet</intervention_name>
    <arm_group_label>Brivaracetam 50 mg oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brivaracetam 75 mg oral tablet</intervention_name>
    <arm_group_label>Brivaracetam 75 mg oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brivaracetam 100 mg oral tablet</intervention_name>
    <arm_group_label>Brivaracetam 100 mg oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)</intervention_name>
    <arm_group_label>10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a healthy male or female volunteer aged 18-55 years inclusive&#xD;
&#xD;
          -  Subject has a Body Mass Index (BMI) of 18.0 - 30.0 kg/m^2 and a weight of at least 50&#xD;
             kg (males) or 45 kg (females)&#xD;
&#xD;
          -  Subject has normal vital signs values, Electrocardiograms (ECGs) and clinical&#xD;
             laboratory values&#xD;
&#xD;
          -  Female subjects should have a negative pregnancy test or be of non-childbearing&#xD;
             potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteer has participated or is participating in any other clinical studies of&#xD;
             investigational drug or another Investigational Medicinal Product (IMP) within the&#xD;
             last 3 months&#xD;
&#xD;
          -  Volunteer is not healthy (eg, taking any drug treatments, excessive amount of alcohol,&#xD;
             cigarettes or caffeine, having any medical or emotional/psychological problems, a&#xD;
             drug/alcohol abuse, having abnormal safety parameters)&#xD;
&#xD;
          -  Subject has an intolerance or allergy against the compound or related drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>February 19, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>April 12, 2013</last_update_submitted>
  <last_update_submitted_qc>April 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Brivaracetam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

